NCT03642496 is a EARLY_PHASE1 clinical trial of Low dose ET019002- T Cells in B-Cell Malignancies, sponsored by First Affiliated Hospital Xi'an Jiaotong University.

Who is sponsoring NCT03642496?

NCT03642496 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT03642496?

Interventions in NCT03642496: Low dose ET019002- T Cells, Middle dose ET019002- T Cells, High dose ET019002- T Cells.

What condition does NCT03642496 study?

NCT03642496 studies B-Cell Malignancies.

Is NCT03642496 still recruiting?

NCT03642496 is currently status unknown. Last updated 23 August 2018.

Last reviewed 2018-08-23 · How we verify

NCT03642496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

Status unknown EARLY_PHASE1 Last updated 23 August 2018

What this trial tests

EARLY_PHASE1 trial testing Low dose ET019002- T Cells in B-Cell Malignancies in 18 participants. Status unknown.

Timeline

19 August 2018

Primary endpoint
19 August 2020

20 September 2020

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	19 August 2018
Primary completion	19 August 2020
Estimated completion	20 September 2020

Drugs / interventions tested

Low dose ET019002- T Cells — full drug profile →
Middle dose ET019002- T Cells — full drug profile →
High dose ET019002- T Cells — full drug profile →

Conditions studied

B-Cell Malignancies — all drugs for B-Cell Malignancies →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

Adults 6 to 80, any sex, with B-Cell Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to determine the safety, including potential dose limiting toxicities, and efficiency of ET019002-T cells and the duration of in vivo survival of ET019002-T cells in patients with relapsed/refractory B-Cell Malignancies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A close look at current γδ T-cell immunotherapy.
Ma L, Feng Y, Zhou Z. · · 2023 · cited 35× · PMID 37063836 · DOI 10.3389/fimmu.2023.1140623
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.
He P, Liu H, Zimdahl B, Wang J, et al · · 2023 · cited 13× · PMID 35776199 · DOI 10.1007/s00432-022-04132-9
Concept CARs are picking up speed.
Mansilla-Soto J, Milone MC. · · 2025 · cited 1× · PMID 40340247 · DOI 10.1016/j.ymthe.2025.05.008

Verify or expand the search:

Other recruiting trials for B-Cell Malignancies

Currently open trials in the same condition.

NCT05683717 — A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies · Phase 1 · recruiting
NCT04509700 — Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies o · Phase 2 · active not recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03642496 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 23 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03642496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing